7 results about "Atypical hyperplasia" patented technology

The present disclosure provides compositions and methods for distinguishing between non-cancerous, pre-cancerous, and cancerous conditions in the esophagus. In particular, the present disclosure provides compositions and methods for distinguishing non-dysplastic Barrett's esophagus (NDBE) samples from pre-cancerous (e.g., low-grade or high-grade dysplasia) and / or cancerous (e.g., esophageal adenocarcinoma) samples based on methylation status and / or DNA copy number abnormalities.

The invention discloses a traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine formulas. The traditional Chinese medicine composition comprises the following components in parts by weight: 16-20 parts of Zhejiang radix ophiopogonis, 15-20 parts of moutan bark, 28-32 parts of salvia miltiorrhiza, 10-14 parts of pseudo-ginseng slices, 15-18 parts of curcuma zedoary, 18-22 parts of codonopsis pilosula, 28-32 parts of astragalus membranaceus and 28-32 parts of oldenlandia diffusa. The preparation method comprises the following steps: (1) cleaning the medicinal materials, and then cutting into small blocks to obtain a mixed medicinal material; (3) boiling with big fire after soaking, continuing to decoct with small fire, and filtering to obtain first medicine liquid and medicine residues; and (4) adding water again, boiling with big fire, continuously decocting with small fire, filtering to obtain a second liquid medicine, and mixing the first liquid medicine and the second liquid medicine. The traditional Chinese medicine composition can obviously improve inflammation and atrophic lesion of gastric mucosa, and has a remarkable effect on treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia.

The invention belongs to the technical field of biological medicine, and particularly relates to application of vitamin B12 in preparation of an auxiliary therapeutic agent for preventing or treating colorectal cancer precancerous lesions. The invention aims to solve the technical problem of providing a novel prevention and intervention means for colorectal cancer (CAC) caused by the cancerization process of colorectal adenoma and inflammatory atypical hyperplasia. The invention further provides a preparation method of the novel prevention and intervention means for the colorectal cancer caused by the cancerization process of the colorectal adenoma and the inflammatory atypical hyperplasia of the colorectal adenoma and the colorectal cancer caused by the inflammatory atypical hyperplasia of the colorectal adenoma. In a colorectal adenoma canceration process, the level of vitamin B12 in a circulatory system is reduced along with the development of diseases. In inflammatory and hereditary colorectal cancer mouse models, MHC-II signals can be enhanced by supplementing medicine vitamin B12, and CD4 effect memory T cell immunity can be reactivated. The invention provides a new thought for further researching the immune recovery strategy in the colorectal cancer precancerous lesion process and the medical application of the vitamin B12.

The invention belongs to the technical field of biology, and discloses application of Prc1 in analysis of liver cell ploidy, liver regeneration capacity and liver function and construction of a liver cell proliferation inhibition or liver surface dysplasia animal model. Specifically, the expression level of Prc1 is negatively correlated with the ploidy of liver cells, is positively correlated with the liver regeneration capacity after liver injury, and is positively correlated with the liver function of a liver cirrhosis patient. In addition, the invention provides an animal model of which Prc1 expression is specifically knocked out of hepatocytes to change the ploidy of the hepatocytes and inhibit proliferation when the hepatocytes are damaged, and an animal model of which atypical hyperplasia appears on the surface of the liver when the hepatocytes are damaged by CCl4, and the like. According to the present invention, the Prc1 is the key gene for regulating and controlling the liver cell ploidy, and the abnormal cell nucleus is accumulated through DNA damage accumulation, mitosis metaphase retardation, sister dyeing monomer separation failure and the like after the Prc1 is specifically knocked out from the liver cell, such that the liver cell ploidy is increased, and the liver regeneration ability and the liver function after the liver injury are affected; and a new target spot and a new model tool are provided for liver regeneration regulation and control.

The application discloses a clinical decision support system based on a thyroid atypical hyperplasia special disease library and a construction method thereof. The method comprises the following steps: collecting thyroid hyperplasia related multi-source heterogeneous data, performing feature extraction on the multi-source heterogeneous data, and constructing a multi-modal database based on the multi-source heterogeneous data after the feature extraction; based on the data contained in the multi-modal database, using an engine decision tree corresponding to a processing rule of thyroid hyperplasia and a data prediction model corresponding to a graph neural network, a corresponding processing strategy is obtained; based on the processing feedback data of thyroid hyperplasia, the multi-modal database and the processing strategy are updated through an incremental learning mechanism and a federated learning mechanism.

The invention provides an endometrial receptivity state detection marker combination, an application of the endometrial receptivity state detection marker combination and a kit, and relates to the technical field of biological medicines. Patients with endometrial atypical hyperplasia or endometrial cancer (AH / EC) with different endometrial receptivity state detection results ('receptivity period 'and'non-receptivity period') are analyzed, and the proteomics relationship among tissues, serum and urine samples is explored. Differential expression proteins identified in three sample types are integrated, molecular changes related to the endometrial receptivity state are researched, and the research result shows that the serum and urine differential proteins can serve as indexes of endometrial tissue function changes. In serum, differential proteins are mainly associated with cholesterol metabolism, immune response and blood coagulation. In urine, differential proteins are mainly related to immune functions and metabolic processes. Differential proteins found in serum and urine both reflect immune and metabolic conditions.

This invention relates to a multimodal imaging capsule endoscopy system, comprising: a capsule endoscope, an external wireless power supply module, and an image receiving and processing module. The capsule endoscope includes a white light and narrow band imaging module for acquiring white light and narrow band images, an autofluorescence imaging module for acquiring autofluorescence images, a wireless transmission module for transmitting the white light, narrow band, and autofluorescence images to the external image receiving and processing module, a light source control module for controlling the on / off state of different light sources within the capsule endoscope, a wireless power supply receiving module for providing power to the capsule endoscope, a position control module for controlling the position and orientation of the capsule endoscope in the gastrointestinal tract, and a capsule shell encapsulation. The external wireless module provides power to the capsule endoscope via the wireless power supply receiving module. The image receiving and processing module receives and analyzes images acquired by the capsule endoscope via the wireless transmission module. Compared with existing technologies, this invention achieves sensitive, accurate, and non-destructive detection of early-stage atypical hyperplasia or superficial gastrointestinal cancer, significantly reducing missed detections and false positives.